May 2nd, 12:00 AM

National Inpatient Sample Analysis: Examining Clinical Outcomes in Cardiac Ablation Patients with Hyperlipidemia

Tony Elias  
*Rowan University*

Mena Elmalh  
*Rowan University*

Kyrillos Girgis  
*Newark Beth Israel Medical Center*

Taha Syed  
*Virtua Health*

Rafail Beshai  
*Jefferson Health NJ*

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

Part of the Cardiology Commons, Cardiovascular Diseases Commons, Health and Medical Administration Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, and the Therapeutics Commons

Let us know how access to this document benefits you - share your thoughts on our feedback form.

Elias, Tony; Elmalh, Mena; Girgis, Kyrillos; Syed, Taha; and Beshai, Rafail, "National Inpatient Sample Analysis: Examining Clinical Outcomes in Cardiac Ablation Patients with Hyperlipidemia" (2024). *Rowan-Virtua Research Day*. 72.  
https://rdw.rowan.edu/stratford_research_day/2024/may2/72

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.
Cardiac ablation, utilizing radiofrequency or cryoablation, is a therapeutic approach for correcting abnormal heart rhythms by disrupting specific electrical pathways within the heart. Despite the growing utilization of cardiac ablation, limited research exists on the impact of hyperlipidemia, a prevalent cardiovascular risk factor, on outcomes in patients undergoing this procedure. Previous studies underscore the importance of understanding how comorbid conditions, such as hyperlipidemia, influence the efficacy and safety of cardiac ablation. Consequently, this study aimed to leverage the national inpatient sample database to investigate in-hospital outcomes among cardiac ablation patients with hyperlipidemia.

Methods

Data from the National Inpatient Sample (NIS) Database for 2019 and 2020 were extracted to identify adult patients who underwent cardiac ablation, stratified based on a concomitant diagnosis of hyperlipidemia using international classification of diseases 10th revision codes. Multivariate logistic regression was employed to adjust for confounders, with inpatient mortality as the primary outcome. Statistical analyses were conducted using SPSS software.

Results

The study encompassed 25,754 cardiac ablation patients, of whom 14,800 (57.4%) had hyperlipidemia. Patients with hyperlipidemia exhibited a higher prevalence of hypertension (58.8% vs. 51%, P<0.001) and chronic kidney disease (26.7% vs. 23.6%, P<0.001) compared to those without hyperlipidemia. In-hospital mortality was significantly elevated among patients with hyperlipidemia (1.3% vs. 1.2%, P<0.001), with multivariate regression demonstrating a higher risk of inpatient mortality (OR 1.799, 95% CI 1.650-1.961, P<0.001). Secondary analysis revealed increased odds of adverse events including ventricular arrhythmia, acute kidney failure, stroke, and deep vein thrombosis among patients with hyperlipidemia.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventricular Arrhythmia</td>
<td>2.393</td>
<td>2.309-2.480</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Acute Kidney Failure</td>
<td>2.503</td>
<td>2.424-2.585</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Stroke</td>
<td>2.868</td>
<td>2.725-3.019</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>DVT</td>
<td>2.312</td>
<td>2.067-2.587</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

Conclusion

This nationally representative retrospective cohort study highlights the association between hyperlipidemia and adverse outcomes, including increased mortality, among patients undergoing cardiac ablation. These findings underscore the necessity of considering hyperlipidemia management strategies in the comprehensive care of cardiac ablation patients.

References